Full Generic Medicine Info
Dosage/Direction for Use

Hypotensive states
Adult: Initially, 15-100 mg in 500 mL of NaCl 0.9% or dextrose 5% inj via infusion, adjusting the dose at least after 10 min to maintain BP. Severe shock: Initially, 0.5-5 mg via direct inj, followed by infusion of 15-100 mg in 500 mL of diluent.
Concurrent use w/ halogenated hydrocarbon anaesth.
Special Precautions
Patient w/ HTN, DM, heart or thyroid diseases, cirrhosis. May provoke relapse in patients w/ history of malaria. Monitoring Parameters Monitor BP.
Adverse Reactions
HTN, headache, tachycardia. Rarely, abscess formation, tissue necrosis, sloughing.
Potentially Fatal: Ventricular arrhythmia (in patient w/ Laennec's cirrhosis).
Symptoms: Severe HTN, headache, constricting chest sensation, nausea, vomiting, euphoria, diaphoresis, pulmonary oedema, tachycardia, bradycardia, sinus arrhythmia, atrial/ventricular arrhythmia, MI, cardiac arrest, convulsion. Management: Employ gastric lavage or induce emesis if the drug is ingested. Local ice packs may delay absorption if drug is administered via IM/SC inj. α-adrenergic blockers may be useful against HTN and arrhythmia. Parenteral diazepam may be given for convulsion.
Drug Interactions
Increased action w/ MAOI and TCA. Decreased pressor effect w/ α-adrenergic blockers. May cause ectopic arrhythmia w/ digitalis.
Potentially Fatal: Halogenated hydrocarbon anaesth, particularly cyclopropane and halothane, may increase the sensitivity of myocardium to the effects catecholamines.
Metaraminol is a potent sympathomimetic amine that increases both systolic and diastolic BP. It has direct actions on α- and β-adrenergic receptors causing peripheral vasoconstriction and positive inotropic effects. It also displaces norepinephrine from adrenergic stores and competitively inhibits its uptake. The overall effect is to increase cardiac output, peripheral resistance, and BP.
Onset: 1-2 min (IV); approx 10 min (IM); 5-20 min (SC).
Duration: Approx 20 min (IV); approx. 1 hr (IM).
Intravenous: Store below 25°C. Protect from light.
CIMS Class
ATC Classification
C01CA09 - metaraminol ; Belongs to the class of adrenergic and dopaminergic cardiac stimulants excluding glycosides. Used in the treatment of heart failure.
Disclaimer: This information is independently developed by CIMS based on metaraminol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in